Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

This was the first study to investigate the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. A phase II, single-blind, multi-centre, randomised-controlled trial recruited across seven UK sites from September to November 2021, with...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection Vol. 87; no. 3; pp. 230 - 241
Main Authors: Kelly, Eimear, Greenland, Melanie, de Whalley, Philip C.S., Aley, Parvinder K., Plested, Emma L., Singh, Nisha, Koleva, Stanislava, Tonner, Sharon, Macaulay, Grace C., Read, Robert C., Ramsay, Mary, Cameron, J.Claire, Turner, David P.J., Heath, Paul T., Bernatoniene, Jolanta, Connor, Philip, Cathie, Katrina, Faust, Saul N., Banerjee, Indraneel, Cantrell, Liberty, Mujadidi, Yama F., Belhadef, Hanane Trari, Clutterbuck, Elizabeth A., Anslow, Rachel, Valliji, Zara, James, Tim, Hallis, Bassam, Otter, Ashley David, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S., Minassian, Angela M., Liu, Xinxue, Snape, Matthew D.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-09-2023
The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association
Subjects:
Adolescents
BNT162b2
Breakthrough infection
COVID-19
Heterologous
Immunisation
Immunity
NVXCoV2373
SARS-CoV-2
Vaccination
COVID-19
SARS-CoV-2
BNT162b2
NVXCoV2373
Vaccination
Immunisation
Adolescents
Heterologous
Immunity
Breakthrough infection
adolescents
breakthrough infection
heterologous
Omicron
Vaccines
immunity
vaccination
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This was the first study to investigate the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. A phase II, single-blind, multi-centre, randomised-controlled trial recruited across seven UK sites from September to November 2021, with follow-up visits to August 2022. Healthy 12-to-16 years olds were randomised (1:1:1) to either 30 µg BNT162b2 (BNT-30), 10 µg BNT162b2 (BNT-10), or NVX-CoV2373 (NVX), 8 weeks after a first 30 µg dose of BNT162b2. The primary outcome was solicited systemic reactions in the week following vaccination. Secondary outcomes included immunogenicity and safety. ‘Breakthrough infection’ analyses were exploratory. 148 participants were recruited (median age 14 years old, 62% female, 26% anti-nucleocapsid IgG seropositive pre-second dose); 132 participants received a second dose. Reactions were mostly mild-to-moderate, with lower rates in BNT-10 recipients. No vaccine-related serious adverse events occurred. Compared to BNT-30, at 28 days post-second dose anti-spike antibody responses were similar for NVX (adjusted geometric mean ratio [aGMR]) 1.09 95% confidence interval (CI): 0.84, 1.42] and lower for BNT-10 (aGMR 0.78 [95% CI: 0.61, 0.99]). For Omicron BA.1 and BA.2, the neutralising antibody titres for BNT-30 at day 28 were similar for BNT-10 (aGMR 1.0 [95% CI: 0.65, 1.54] and 1.02 [95% CI: 0.71, 1.48], respectively), but higher for NVX (aGMR 1.7 [95% CI: 1.07, 2.69] and 1.43 [95% CI: 0.96, 2.12], respectively). Compared to BNT-30, cellular immune responses were greatest for NVX (aGMR 1.73 [95% CI: 0.94, 3.18]), and lowest for BNT-10 (aGMR 0.65 [95% CI: 0.37, 1.15]) at 14 days post-second dose. Cellular responses were similar across the study arms by day 236 post-second dose. Amongst SARS-CoV-2 infection naïve participants, NVX participants had an 89% reduction in risk of self-reported ‘breakthrough infection’ compared to BNT-30 (adjusted hazard ratio [aHR] 0.11 [95% CI: 0.01, 0.86]) up until day 132 after second dose. BNT-10 recipients were more likely to have a ‘breakthrough infection’ compared to BNT-30 (aHR 2.14 [95% CI: 1.02, 4.51]) up to day 132 and day 236 post-second dose. Antibody responses at 132 and 236 days after second dose were similar for all vaccine schedules. Heterologous and fractional dose COVID-19 vaccine schedules in adolescents are safe, well-tolerated and immunogenic. The enhanced performance of the heterologous schedule using NVX-CoV2373 against the Omicron SARS-CoV-2 variant suggests this mRNA prime and protein-subunit boost schedule may provide a greater breadth of protection than the licensed homologous schedule. National Institute for Health Research and Vaccine Task Force. International Standard Randomised Controlled Trial Number registry: 12348322. •Heterologous and fractional dose COVID-19 vaccine schedules in adolescents are safe, well-tolerated and immunogenic.•NVXCoV2373 following 30µg BNT162b2 as a first dose elicited the highest humoral and peak cellular immune responses.•Neutralising antibodies against Omicron BA.1 and BA.2 were higher after NVXCoV2373 than a two-dose 30µg BNT162b2 schedule.•The lowest rate of SARS-CoV-2 breakthrough infections occurred in participants who received NVXCoV2373 as their second dose.•Enhanced protection may be provided by heterologous vaccine schedules using NVXCoV2373 than the homologous BNT162b2 schedule.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
Members of the Com-COV3 Study Group are listed in the Supplement.
Contributed equally and are joint first authors
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2023.06.007